Vitamin B3 shows promise in reducing skin cancer risk for leukemia patients

NCT ID NCT04844528

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study tests whether taking nicotinamide (a form of vitamin B3) twice daily can lower the risk of new non-melanoma skin cancers in people with chronic lymphocytic leukemia (CLL) who have already had at least one skin cancer. About 86 participants will be randomly assigned to receive either nicotinamide or a placebo for one year, then all will receive nicotinamide for another year. The goal is to see if this simple vitamin can help control skin cancer development in this higher-risk group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huntsman Cancer Institute at University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.